ANIPのチャート
ANIPの企業情報
| symbol | ANIP |
|---|---|
| 会社名 | ANI Pharmaceuticals Inc （ANIファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ANIファーマシューティカル（ANI Pharmaceuticals Inc.）は統合・専門的製薬会社である。同社はブランド医薬品とジェネリック医薬品の開発、製造、マーケティングに従事する。同社は抗癌剤（抗腫瘍剤）、ホルモンおよびステロイド、複合的製剤を提供する。同社はまた、他の製薬会社の請負製造を行う。製品には、ブランド医薬品とジェネリック医薬品を含む。ジェネリック医薬品はエリスロマイシンエチルコハク酸塩、メチルテストステロン（EEMT）を有するエステル化エストロゲン、エトドラクフェノフィブレート、フレカイニド、フルボキサミン、メタゾラミド、メトクロプラミドシロップニルタミド、ニモジピン、アヘンチンキ、オキシコドンカプセル、オキシコドン経口溶液、プロパフェノンおよびバンコマイシンなどを含む。ブランド製品にはコルテネーマ、インデラルLA、リトビッド、レグランおよびバンコシンが含まれる。同社の医薬品製造施設はミネソタ州ボーデットに位置する。 ANIファ―マシュ―ティカルズは米国の製薬会社。ブランドとジェネリックの医療用医薬品の開発、製造、販売に従事する。女性の性的健康、更年期障害、避妊と男性性腺機能低下症の治療用医薬品開発のほか、開発製品の対象は麻酔薬、抗がん薬、ホルモン・ステロイドおよび製剤を含む。本社はミネソタ州。 ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. |
| 本社所在地 | 210 Main Street West Baudette MN 56623 USA |
| 代表者氏名 | Robert E. Brown ロバートE.ブラウン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 218-634-3500 |
| 設立年月日 | 35278 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 173人 |
| url | www.anipharmaceuticals.com |
| nasdaq_url | https://www.nasdaq.com/symbol/anip |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 62.04800 |
| 終値（lastsale） | 54.83 |
| 時価総額（marketcap） | 648570965.63 |
| 時価総額 | 時価総額（百万ドル） 656.49620 |
| 売上高 | 売上高（百万ドル） 189.20100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 806.10820 |
| 当期純利益 | 当期純利益（百万ドル） 13.49700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ANI Pharmaceuticals Inc revenues increased 15% to $93.8M. Net income applicable to common stockholders increased 31% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Stock-based Compensation in SGA decrease of 3% to $2.7M (expense). |
ANIPのテクニカル分析
ANIPのニュース
ANI Pharmaceuticals (ANIP) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow (NASDAQ:ANIP) 2022/09/13 14:23:07 Seeking Alpha
The following slide deck was published by ANI Pharmaceuticals, Inc.
UPDATE: H.C. Wainwright Starts ANI Pharmaceuticals at Buy 2022/09/07 10:35:12 Investing.com
https://www.investing.com/news/pro/hc-wainwright-starts-ani-pharmaceuticals-at-buy-432SI-2887321
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022/08/30 20:05:00 Wallstreet:Online
ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference as follows: Date: Monday,
ANI Pharmaceuticals Gets FDA Approval For Dexamethasone Tablets USP 2022/08/16 12:39:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) said on Tuesday that it has received approval from the FDA for the Abbreviated New Drug Application for Dexamethasone Tablets USP 1.5mg, 4mg…
ANI Pharmaceuticals'' generic dexamethasone tablets get FDA approval 2022/08/16 11:10:18 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) approved ANI Pharmaceuticals'' (ANIP) generic dexamethasone tablets USP 1.5mg, 4mg and 6mg
Mid-Afternoon Market Update: Nasdaq Rises Over 200 Points; ANI Pharmaceuticals Shares Slide 2022/03/15 18:42:06 Benzinga
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 350 points on Tuesday. The Dow traded up 1.07% to 33,297.32 while the NASDAQ rose 1.81% to 12,809.09. The S&P also rose, gaining, 1.24% to 4,224.97. Also check this: Executives Sell More Than $25M Of 4 Stocks Leading and Lagging Sectors Consumer discretionary shares climbed by 2.7% on Tuesday. Meanwhile, top gainers in the sector included New Oriental Education & Technology Group Inc. (NYSE: EDU ), up 20% and Shift Technologies, Inc. (NASDAQ: SFT ) up 15%. In trading on Tuesday, energy shares fell by 3.3%. Top Headline US producer prices rose 0.8% from a month ago in February, versus a revised 1.2% increase in the previous month and slightly below analysts’ estimates of 0.9%. Equities Trading UP Incannex Healthcare Limited (NASDAQ: IXHL ) shares shot up 136% to $54.00 after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).
ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q4 2021 Results - Earnings Call Transcript 2022/03/15 17:42:07 Seeking Alpha
ANI Pharmaceuticals Down 25% After Earnings Miss 2022/03/15 16:59:33 Investing.com
https://www.investing.com/news/stock-market-news/ani-pharmaceuticals-down-25-after-earnings-miss-2785166
ANI Pharma reaches a seven-month low on soft guidance for 2022 2022/03/15 14:27:22 Seeking Alpha
The shares of ANI Pharmaceuticals <> have approached the lowest level since August after the maker of branded and generic medicines posted a lower than expected guidance for 2022
ANI Pharma''s Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus 2022/03/15 13:31:14 Benzinga
ANI Pharmaceuticals Inc''s (NASDAQ: ANIP ) Q4 revenues were $60.9 million , +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for generic pharmaceutical products were $41.6 million, +8% primarily due to the Novitium acquisition and Q3 launch of Nebivolol, tempered by sales declines for Tolterodine and Vancomycin and lower … Full story available on Benzinga.com
FTC final order settling antitrust charges clears way for ANI acquisition of Novitium 2022/01/12 18:32:27 Seeking Alpha
The Federal Trade Commission has issued a final order that clears the way for ANI Pharmaceuticals'' $210M acquisition of privately held Novitium Pharma
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by New York State Teachers Retirement System 2021/12/24 09:24:41 Transcript Daily
New York State Teachers Retirement System lowered its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,780 shares of the specialty pharmaceutical companys stock after selling 400 shares during the quarter. []
Cancer Cachexia Market Size [2021-2028] | is Projected to Reach USD 2.93 Billion 2021/12/16 06:48:00 Intrado Digital Media
Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others. Key Players covered in the Cancer Cachexia Market Research Report are Bristol-Myers Squibb Company, New York, U.S., ANI Pharmaceuticals, Inc., Baudette, U.S., Merck & Co., Inc., Kenilworth, U.S., Hikma Pharmaceuticals PLC, London, U.K., Mylan N.V., Pennsylvania, U.S., AbbVie, Inc., North Chicago, U.S., Pfizer Inc., New York, U.S., Teva Pharmaceutical Industries Ltd., Petach-Tikva, Israel and others.
Morgan Stanley Has $3.73 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) 2021/12/11 09:14:42 Dakota Financial News
Morgan Stanley lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 106,418 shares of the specialty pharmaceutical companys stock after selling 2,360 shares during the period. Morgan Stanleys holdings in ANI Pharmaceuticals were worth $3,730,000 as of its most recent filing with the []
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Buys $98,450.00 in Stock 2021/12/07 22:28:42 Dakota Financial News
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey bought 2,500 shares of the companys stock in a transaction that occurred on Monday, December 6th. The shares were bought at an average cost of $39.38 per share, for a total transaction of $98,450.00. The transaction was disclosed in a document filed with the SEC, which is available []